The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Targeting Cdc20 as a novel cancer therapeutic strategy
Open accessAbstract
The Anaphase Promoting Complex (APC, also called APC/C) regulates cell cycle progression by forming two closely related, but functionally distinct E3 ubiquitin ligase sub-complexes, APCCdc20 and APCCdh1, respectively. Emerging evidence has begun to reveal that Cdc20 and Cdh1 have opposing functions in tumorigenesis. Specifically, Cdh1 functions largely as a tumor suppressor, whereas Cdc20 exhibits an oncogenic function, suggesting that Cdc20 could be a promising therapeutic target for combating human cancer. However, the exact underlying molecular mechanisms accounting for their differences in tumorigenesis remain largely unknown. Therefore, in this review, we summarize the downstream substrates of Cdc20 and the critical functions of Cdc20 in cell cycle progression, apoptosis, ciliary disassembly and brain development. Moreover, we briefly describe the upstream regulators of Cdc20 and the oncogenic role of Cdc20 in a variety of human malignancies. Furthermore, we summarize multiple pharmacological Cdc20 inhibitors including TAME and Apcin, and their potential clinical benefits. Taken together, development of specific Cdc20 inhibitors could be a novel strategy for the treatment of human cancers with elevated Cdc20 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Nasmyth, K. (2001) · Annual Review of Genetics · doi:10.1146/annurev.genet.35.102401.091334 · Cited by 805
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185
Li, X., Zhu, F., Jiang, J., Sun, C., Wang, X., Shen, M., Tian, R., Shi, C., Xu, M., Peng, F., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.026 · Cited by 116
New orally active proteasome inhibitors in multiple myeloma
Allegra, A., Alonci, A., Gerace, D., Russo, S., Innao, V., Calabrò, L., & Musolino, C. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.10.018 · Cited by 74
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Huang, C., Chen, L., Savage, S. R., Eguez, R. V., Dou, Y., Li, Y., da Veiga Leprevost, F., Jaehnig, E. J., Lei, J. T., Wen, B., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.007 · Cited by 360
The Role of Curcumin in Cancer Treatment
Zoi, V., Galani, V., Lianos, G. D., Voulgaris, S., Kyritsis, A. P., & Alexiou, G. A. (2021) · Biomedicines · doi:10.3390/biomedicines9091086 · Cited by 315
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Qi, S.-M., Dong, J., Xu, Z.-Y., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 292
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Metadata
- Authors
- Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z., & Wei, W.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 151
- Pages
- 141-151
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1984168218
- Cited by
- 251
- References
- 5
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Cdc20 as a novel cancer therapeutic strategy. https://app.cochat.ai/papers/10.1016/j.pharmthera.2015.04.002
- The paper
- Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z., & Wei, W. (2015). Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2015.04.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.